| Previous close | 4,467.50 |
| Open | 4,476.50 |
| Bid | 4,352.00 x 6100 |
| Ask | 4,535.00 x 13000 |
| Day's range | 4,466.50 - 4,525.00 |
| 52-week range | 3,996.00 - 5,520.00 |
| Volume | 1,335,782 |
| Avg. volume | 2,202,226 |
| Market cap | 56.72B |
| Beta | 0.62 |
| PE ratio (TTM) | 16.78 |
| EPS (TTM) | 267 |
| Earnings date | 9 Nov 2017 |
| Dividend & yield | 2.79 (4.86%) |
| Ex-dividend date | 2017-08-10 |
| 1y target est | 62.72 |
- Reuters•8 hours ago
FDA expands use of AstraZeneca/Merck ovarian cancer drug
The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.
- Reuters•8 hours ago
FDA approves expanded use of AstraZeneca ovarian cancer drug
The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.
- TheStreet.com•3 days ago
Shire Gains as it Seeks European Approval For Dry Eye Treatment
The drug would be the first such treatment in Europe.
